ライフサイエンスコーパス: event-free

1 outcome in those subjects who are currently event free.

2 y 60% of admissions were recorded as adverse event free.

3 Three-year event-free (79% vs 79%; P = .842) and overall survival (

4 To investigate adverse event free admissions as a potential, patient-centered i

5 We defined adverse event free admissions as those without record of any of

6 -adjusted hospital-specific rates of adverse event free admissions for colorectal procedures showed 1

7 -adjusted hospital-specific rates of adverse event free admissions were calculated using colorectal p

8 Secondary endpoints included event-free and overall survival (intention-to-treat anal

9 KC1 expression correlated strongly with poor event-free and overall survival (P < 0.0001), independen

10 lower complete remission rates, and shorter event-free and overall survival in older (age >/=60 y) a

11 The 5-year event-free and overall survival rates were, respectively

12 er neoadjuvant anti-HER2 therapy have longer event-free and overall survival than do patients without

13 rsistent mutations had significantly reduced event-free and overall survival vs the 26 who cleared al

14 After a median follow-up time of 84 months, event-free and overall survival were not different betwe

15 for the prespecified secondary endpoints of event-free and overall survival, and assess the associat

16 Systemic therapy has improved osteosarcoma event-free and overall survival, but 30-50% of patients

17 Secondary end points included event-free and overall survival, treatment toxicity, and

18 Both cohorts experienced similar event-free and overall survival.

19 , 6, and 12 months) and predicted for longer event-free and transformation-free survival.

20 re no longer prognostic in patients who were event free at 1 year.

21 Patients with cHL who are event free at 2 years have an excellent outcome regardle

22 For advanced-stage patients who were event free at 2 years, the 5-year risk of relapse was on

23 ut diminished to 5.6% for patients remaining event free at 2 years.

24 elapse was only 7.6%, and for those who were event free at 3 years, it was comparable to that of limi

25 Among those who were event-free at 12 months, rates of MI or stent thrombosis

26 gust 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate

27 and nine had sufficient follow-up data to be event-free at 24 months.

28 within 10 years), sex-, and race-matched and event-free controls from among 2023 consecutive patients

29 ensity for the index event and the number of event-free days.

30 The 5-year event-free, disease-free, and overall survival rates are

31 0.1% by FC) were evaluated by HTS and FC for event-free (EFS) and overall survival (OS).

32 assessment and analysed survival endpoints (event-free, failure-free, transformation-free, and overa

33 6,454 untreated and 7,046 treated), who were event free for 3 years, were included in the analysis.

34 Event-free mean (SD) time was 7.99 (0.43) years for high

35 n between pathological complete response and event-free or overall survival (analysed by landmark ana

36 t also predicted for improved probability of event-free (P = .043; e14a2) and transformation-free sur

37 One hundred and sixty-nine consecutive event-free patients of the randomized EXAMINATION study

38 ldren, the Ross procedure had a 12.7% higher event-free probability (death or any reintervention) at

39 ults, where the bioprosthesis had the lowest event-free probability of 78.8%, followed by comparable

40 An event-free recovery occurred frequently after laparoscop

41 Event-free recovery was seen in 85% in the laparoscopic

42 paroscopic surgery and male sex predicted an event-free recovery.

43 dropout of patients, the healing pattern in event-free ST-segment-elevation myocardial infarction pa

44 At 2 years, event free survival (EFS) and overall survival (OS) were

45 5-year event free survival significantly differed between the i

46 Clinical efficacy assessments included event free survival, and change from baseline of two ass

47 Four-year event-free survival (+/- standard deviation [SD]) did no

48 s needing scar dechanneling alone had better event-free survival (80% versus 62%) and lower mortality

49 There were no significant differences in event-free survival (90.0% +/- 4.7% [SE] v.

50 BI patients achieved significantly prolonged event-free survival (90.1% [95% confidence interval, 88.

51 One-year Kaplan-Meier estimates of adverse event-free survival (death, heart failure hospitalizatio

52 ars earlier (p = 0.002) and had worse 4-year event-free survival (death, myocardial infarction, strok

53 n non-DS patients, resulting in lower 8-year event-free survival (EFS) (64% +/- 2% vs 81% +/- 2%, P <

54 genetic profile and a significantly improved event-free survival (EFS) (94%) compared with patients w

55 The primary objective was 1-year event-free survival (EFS) after HLA allele-matched (at H

56 Survivor functions for event-free survival (EFS) and OS were estimated using th

57 e remission) was the primary end point, with event-free survival (EFS) and overall survival (OS) as s

58 adding GO to standard chemotherapy improved event-free survival (EFS) and overall survival (OS) in c

59 ated the hazard ratios (HRs) and 95% CIs for event-free survival (EFS) and overall survival (OS) usin

60 s old; median follow-up, 5.38 years), 5-year event-free survival (EFS) and overall survival (OS) were

61 cology Group study AREN0534 aimed to improve event-free survival (EFS) and overall survival (OS) whil

62 avorable-histology Wilms tumors (FHWTs) with event-free survival (EFS) and overall survival (OS) with

63 To quantify the relationships between event-free survival (EFS) and overall survival (OS) with

64 Four-year event-free survival (EFS) and overall survival estimates

65 We have previously shown that event-free survival (EFS) at 24 months (EFS24) is a clin

66 Purpose To investigate whether event-free survival (EFS) can be maintained among childr

67 The median event-free survival (EFS) for the entire study populatio

68 The primary objective of the trial was event-free survival (EFS) from randomization.

69 the risk for relapse and the probability of event-free survival (EFS) in children with acute lymphob

70 ad morphologic induction failure with 5-year event-free survival (EFS) of 50.7% (95% CI, 37.4 to 64.0

71 an 8 ng/mL treated with rituximab had 3-year event-free survival (EFS) of 59% and 79% and 3-year over

72 ssigned to Capizzi methotrexate had a 5-year event-free survival (EFS) of 82% versus 75.4% (P = .006)

73 s with end-induction MRD <0.01% had a 5-year event-free survival (EFS) of 87% +/- 1% vs 74% +/- 4% fo

74 h embryonal RMS, have an estimated long-term event-free survival (EFS) of less than 20%.

75 tic Index risk factors and age (> 70 years), event-free survival (EFS) of patients with bulky disease

76 We sought to determine the effect on event-free survival (EFS) of staging variables, extent o

77 MRD-based standard-risk patients, the 5-year event-free survival (EFS) rate was 93% (SE 2%), the 5-ye

78 Overall survival (OS) and event-free survival (EFS) rates at 10 years were, respec

79 9% for TRIL and 41% for DL (P = .78); 4 year event-free survival (EFS) was 27% for TRIL and 27% for D

80 oor-prognosis patients (IPI, 3 to 5); 3-year event-free survival (EFS) was 71%, 75%, and 67%, respect

81 Five-year event-free survival (EFS) was 75.0% in patients with 1q

82 relapses at a median of 11.5 months; 5-year event-free survival (EFS) was 77% (range, 62% to 87%).

83 r overall survival was 95.5%, and the 5-year event-free survival (EFS) was 89.8%.

84 The 3-year overall survival was 94%, and event-free survival (EFS) was 91%.

85 Three-year overall survival and event-free survival (EFS) were 95% and 82%, respectively

86 n and ocular survival, patient survival, and event-free survival (EFS) were calculated and then compa

87 ic factors, early metabolic change, pCR, and event-free survival (EFS) were examined (log-rank test).

88 evaluated in relation to cancer occurrence, event-free survival (EFS), and overall survival (OS).

89 ical benefit, such as disease-free survival, event-free survival (EFS), and overall survival (OS).

90 with decreased 3-year overall survival (OS), event-free survival (EFS), and relapse risk from the end

91 emia of Down syndrome (ML-DS) have favorable event-free survival (EFS), but experience significant tr

92 Secondary end points included 5-year event-free survival (EFS), distant disease-free survival

93 ween the preimatinib and imatinib cohorts in event-free survival (EFS), OS, and relapse-free survival

94 Treatment outcomes included event-free survival (EFS), overall survival (OS), and cu

95 loid leukemia (AML) is associated with worse event-free survival (EFS), overall survival (OS), and cu

96 Five-year event-free survival (EFS), overall survival (OS), and lo

97 primary endpoints were overall survival and event-free survival (EFS), probabilities of overall surv

98 Ph(-) had worse failure-free survival (FFS), event-free survival (EFS), transformation-free survival

99 Primary end points were event-free survival (EFS), treatment discontinuation, no

100 vant therapy, and reports of both pCR and an event-free survival (EFS)-type outcome.

101 The main end point was event-free survival (EFS).

102 The primary end point was event-free survival (EFS).

103 Other outcomes of interest included event-free survival (EFS).

104 ethnicity-were evaluated for their impact on event-free survival (EFS).

105 ues (SUVmax) and total lesion glycolysis, on event-free survival (EFS).

106 ls defined using RNA sequencing with pCR and event-free survival (EFS).

107 CS of more than 2 being associated with poor event-free survival (EFS).

108 rall survival (OS, 46% vs 28%; P < .001) and event-free survival (EFS, 36% vs 21%; P < .001) at 5 yea

109 Event-free survival (EFS, primary endpoint) and other cl

110 ing the greatest prognostic significance for event-free survival (EFS, the main endpoint of the IELSG

111 vage therapy (37% vs 26%; P = .07) and lower event-free survival (EFS; 4-year EFS, 31% vs 43%; P < .0

112 (89% +/- 3% vs 90% +/- 4%; Plog-rank = .64), event-free survival (EFS; 87% +/- 3% vs 89% +/- 4%; Plog

113 e level of MRD was inversely correlated with event-free survival (EFS; P < .004) and positively corre

114 dverse overall survival (OS; P = 0.0441) and event-free survival (EFS; P = 0.0114) compared with low

115 Outcome measures were event-free survival (EFS; primary) and overall survival

116 or International Prognostic Index factors in event-free survival (hazard ratio [HR] of ABC-like disea

117 for death, 0.78; one-sided P=0.009), as was event-free survival (hazard ratio for event or death, 0.

118 nt adverse prognostic marker for hematologic event-free survival (hazard ratio, 2.94; 95% CI, 1.37 to

119 2), translating into a prolonged hematologic event-free survival (hemEFS; median, 46.1 vs 28.1 months

120 2.19, 95% CI 1.25-3.85) and reduced cardiac event-free survival (HR 2.27, 95% CI 1.31-3.94).

121 fect against RB invasion, as demonstrated by event-free survival (HR = 0.53, P = 0.007 for GC versus

122 f 53 months, no differences were detected in event-free survival (HR, 0.99; stratified log-rank P = .

123 ence interval [CI], 1.05-1.87; P < .021) and event-free survival (HR, 1.39; 95% CI, 1.05-1.82; P < .0

124 t vs absent: HR, 0.18; P = .006), and better event-free survival (KIR2DS1 present vs absent: HR, 0.31

125 MOLLI-ECV >/= the median (28.9%) had shorter event-free survival (log-rank, P=0.028).

126 ce, was associated with inferior hematologic event-free survival (median, 3.4 v 8.8 months, respectiv

127 gnificantly correlated with poor overall and event-free survival (P < 0.05).

128 All patients showed a 3-year probability of event-free survival (pEFS) of 55%.

129 ersmith Infant Neurological Examination) and event-free survival (time to death or the use of permane

130 The primary end point was event-free survival (with an event defined as disease pr

131 The 5-year event-free survival (with standard error) did not differ

132 pse risk [RR]: GO 36% v No-GO 34%, P = .731; event-free survival [EFS]: GO 53% v No-GO 58%, P = .456)

133 ed overall survival and subgroup analyses of event-free survival according to disease duration at scr

134 We aimed to assess event-free survival after high-dose chemotherapy with bu

135 s (interquartile range: 7-16 months), median event-free survival after IRE was 8 months (95% confiden

136 Five-year event-free survival after SLN alone was 93% with no isol

137 Cumulative event-free survival after surgery was 72% at 40 years.

138 otherapy significantly prolonged overall and event-free survival among patients with AML and a FLT3 m

139 th inferior transformation-free survival and event-free survival and an independent predictor of infe

140 ed risk stratification trees based on 5 year event-free survival and clinical applicability.

141 Event-free survival and overall survival (OS) hazard rat

142 Event-free survival and overall survival (OS) rates at 2

143 With a median follow-up of 4.8 years, 5-year event-free survival and overall survival (OS) rates were

144 OCTN1 (SLC22A4; ETT) strongly predicts poor event-free survival and overall survival in multiple coh

145 The 5-year event-free survival and overall survival rates+/-SE were

146 The 5-year event-free survival and overall survival were 91.4% (95%

147 Event-free survival and overall survival were determined

148 diagnosis <2 years) results in satisfactory event-free survival and overall survival, and to correla

149 ter chemotherapy) and their association with event-free survival and overall survival.

150 on to offer prognostic significance for both event-free survival and overall survival.

151 The primary outcomes were event-free survival and overall survival.

152 aim was to establish the association between event-free survival and patients' minimal residual disea

153 We aimed to identify predictors of event-free survival and survival with acceptable hrQoL (

154 chemotherapy with or without rituximab, with event-free survival as the primary end point.

155 emission with incomplete recovery), inferior event-free survival as well as overall survival in both

156 ed an overall response, a complete response, event-free survival at 12 months and 24 months from enro

157 The primary end point was event-free survival at 2 years (2-year EFS).

158 Event-free survival at 2 years was 77.0% (95% CI 72.1-82

159 The primary endpoint was non-inferiority of event-free survival at 2 years, analysed by intention to

160 Overall and event-free survival at 3 years were 83.9% and 80.4%, res

161 Starting from randomization, the rate of event-free survival at 4 years was 79% (95% confidence i

162 Event-free survival based on interim PET/CT (RIW) respon

163 group; the unadjusted hazard ratio (HR) for event-free survival between the two randomised HER2-posi

164 and 23 with chemotherapy alone), the HR for event-free survival between those with and without trast

165 70.0 ng/mmol) was associated with 88% 5-year event-free survival compared with 50% with high urinary

166 gnificantly worse overall survival (OS), and event-free survival compared with B-other with a 5-year

167 42, 0.20-0.89, p=0.024) predicted for better event-free survival compared with imatinib 400 mg, but t

168 ents with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non-Ph-l

169 on day 46 seemed to have an inferior 10-year event-free survival compared with the 126 with negative

170 o-group and in one patient in the Epi-group (event-free survival curves by Grey-test, P=0.03).

171 patients, Kaplan-Meier major adverse cardiac event-free survival curves demonstrated a significant be

172 The primary end point of HALT-MS is event-free survival defined as survival without death or

173 Event-free survival did not differ between treatment gro

174 alysis, patients with preeclampsia had worse event-free survival during 1-year follow-up (P=0.047).

175 ach associated with an increased risk for an event-free survival event ( P = .48, P = .08, P = .065,

176 307 event-free survival events were reported (153 in the MAP

177 educed for patients achieving post-treatment event-free survival for 24 months (pEFS24; standardized

178 Three-year event-free survival for all patients (N = 229) was 44% a

179 a QLV ratio </=0.70 had significantly worse event-free survival for all study end points--hazard rat

180 SPIO enhancement was associated with reduced event-free survival for aneurysm rupture or repair (P=0.

181 The groups differed significantly in event-free survival for incident ESRD and composite outc

182 Those with multiple variants had worse event-free survival from all-cause death, cardiac transp

183 x and phenotype, we retrospectively assessed event-free survival from birth to the first clinical vis

184 d a less severe clinical course with greater event-free survival from major cardiac events (P=0.04) c

185 These results show a sustained benefit in event-free survival from trastuzumab-containing neoadjuv

186 th rituximab remained associated with longer event-free survival in a multivariate analysis.

187 The primary endpoint was 2 year event-free survival in all registered eligible patients

188 x of these genes is associated with inferior event-free survival in both patient cohorts.

189 We sought to analyze long-term chimerism and event-free survival in children undergoing transplantati

190 ERPRETATION: Busulfan and melphalan improved event-free survival in children with high-risk neuroblas

191 t of combination cardioprotective therapy on event-free survival in Duchenne muscular dystrophy.

192 Event-free survival in nonobstructive CAD with high CT-L

193 chemotherapy (>/=10% viable tumour) improved event-free survival in patients with high-grade osteosar

194 with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblas

195 Five-year event-free survival in patients with SETBP1 mutations wa

196 after therapy with a histologic response and event-free survival in pediatric and young adult patient

197 Event-free survival in this group was significantly lowe

198 Event-free survival is also reduced in patients with cor

199 The primary outcome measure was event-free survival measured in the intention-to-treat p

200 a median follow-up of 17.1 months and median event-free survival of 17.8 months.

201 n = 92, P < .0001) and 4-year probability of event-free survival of 33 +/- 6% vs 62 +/- 5% (P = .0013

202 ome in the matched HFpEF cohort, with 1-year event-free survival of 62% (95% CI, 60%-64%) versus 65%

203 ated for standard-risk ALL and had a 10-year event-free survival of 88.9% (43.3-98.4).

204 This study sought to determine cardiac event-free survival of a consecutive cohort with suspect

205 With improved event-free survival of patients undergoing primary biopr

206 Although event-free survival or overall survival did not differ b

207 ninferiority was set at -8.5% for the 3-year event-free survival rate (EFS), equivalent to 1.43 in te

208 The primary outcome was one-year event-free survival rate for the combined end point of d

209 f 4.6 years, there was a significantly lower event-free survival rate in patients with ASP progressio

210 atients remained relapse free, with a 2-year event-free survival rate of 50% +/- 8%.

211 e current standard of care and results in an event-free survival rate of 50% to 60%, indicating that

212 2-year event-free survival rate was 81% (95% CI 64-90).

213 hod was used to calculate 5-year overall and event-free survival rates by cancer stage, and the Cox p

214 The 5-year event-free survival rates for patients with stages 0 to

215 t VB stroke (P = .04), with 12- and 24-month event-free survival rates of 78% and 70%, respectively,

216 5% vs 0.9%, P = .00013), resulting in 5-year event-free survival rates of 83.9 +/- 0.9% for dexametha

217 0.45 to 0.98; P=0.04); the estimated 2-year event-free survival rates were 65% (95% CI, 56 to 75) an

218 The 1- and 2-year cumulative event-free survival rates were 87% and 81%.

219 nonobstructive CAD and high CT-LeSc had hard event-free survival similar to patients with obstructive

220 powerful predictor of major adverse cardiac event-free survival than choice of therapy (hazard ratio

221 sociated with a better biomarker profile and event-free survival than HF-REF and HF-PEF.

222 BG led to lower rates of 5-year survival and event-free survival than on-pump CABG.

223 th blinatumomab resulted in a higher rate of event-free survival than that with chemotherapy (6-month

224 We evaluated the risk of relapse at event-free survival time points in cHL and compared the

225 40% (6/15 of evaluable patients) and median event-free survival was 17 months.

226 n follow-up of 20 months, the overall median event-free survival was 18 months: 20 and 13 months for

227 r disease-free survival was 31.2% and 16.2%, event-free survival was 21.5% and 12.9%, and overall sur

228 de, and melphalan group had an event; 3-year event-free survival was 50% (95% CI 45-56) versus 38% (3

229 5 year event-free survival was 58% (95% CI 48-66) in patients i

230 er a median follow-up of 5 years, the 3-year event-free survival was 62% versus 65% ( P = .83).

231 In patients with T-LL, 3-year event-free survival was 63.3% (95% CI, 54.2% to 71.0%),

232 edian 58 months' potential follow-up, 3-year event-free survival was 69% and 3-year overall survival

233 e incidence of EBRT was 5.9% (SE +/- 3), and event-free survival was 69.2% (SE +/- 27.2).

234 Estimated 2-year event-free survival was 69.7% (95% CI 66.2-73.0).

235 37 months (IQR 30-44), the estimated 2 year event-free survival was 75% (95% CI 63-84).

236 Cumulative event-free survival was 76.8% with a high CT-LeSc and 96

237 low-up of 3.77 years (IQR 3.50-4.22), 3-year event-free survival was 78% (95% CI 70-84) in the lapati

238 Overall event-free survival was 78.4% (90% CI, 60.1%-89.0%) at 3

239 months), the overall survival was 91.4%, and event-free survival was 81.4%.

240 At 5 years, event-free survival was 84% +/- 4% (SE) and overall surv

241 Estimated 4-year event-free survival was 89.7% (95% confidence interval 8

242 2 year event-free survival was 92.6% (95% CI 89.6-95.7) for tre

243 Event-free survival was 99.0% at 1 year, 96.2% at 5 year

244 n follow-up of 70 months (IQR 52-91), 5-year event-free survival was better in the augmented treatmen

245 Event-free survival was defined as avoidance of external

246 Although the bleeding event-free survival was different in VWD types, only a B

247 Two-year event-free survival was estimated at 49.0% (95% confiden

248 Kaplan-Meier event-free survival was evaluated in 4 patient subgroups

249 1%] vs. 0 of 37 [0%]), and the likelihood of event-free survival was higher in the nusinersen group t

250 After a median follow-up of 30 months, event-free survival was longer in the rituximab group th

251 Event-free survival was lower with increasing age at tra

252 Long-term post-PMV event-free survival was predicted by age, degree of mitr

253 Median event-free survival was significantly prolonged by LDAC

254 the provisional risk classification, 10-year event-free survival was significantly worse for patients

255 By Kaplan-Meier analysis, event-free survival was significantly worse in patients

256 Event-free survival was strongly associated with patholo

257 deled with treatment x time interaction) for event-free survival were 0.35 (95% CI, 0.16-0.74) at 2 y

258 MSDs; however, estimated 5-year overall and event-free survival were worse for URD recipients (71% a

259 The primary endpoint was 3-year event-free survival, analysed by intention to treat.

260 All 24 (100%) patients met 12-month event-free survival, and nine had sufficient follow-up d

261 ted with the International Prognostic Index, event-free survival, and number of circulating Tregs.

262 ed to investigate time to local progression, event-free survival, and OS.

263 icacy in terms of time to local progression, event-free survival, and overall survival (OS).

264 response rate, similar transplantation rate, event-free survival, and overall survival, less toxicity

265 cluding primary refractoriness and relapse), event-free survival, and overall survival.

266 The 2-year Kaplan-Meier ocular survival, event-free survival, and progression-free survival estim

267 y efficacy end point of the study was 3-year event-free survival, and results were analyzed on an int

268 After a median follow-up of 40.6 months, the event-free survival, cumulative incidence of relapse, an

269 The primary endpoint was event-free survival, defined as being alive without graf

270 The primary end point was event-free survival, defined as time from randomization

271 Secondary end points were event-free survival, overall survival, and safety.

272 elated donors, no significant differences in event-free survival, overall survival, or nonrelapse mor

273 ance therapy after transplantation prolonged event-free survival, progression-free survival, and over

274 er B-cell [GCB]-like DLBCL) were observed in event-free survival, progression-free survival, and over

275 Factors associated with event-free survival, relapse-free survival, and incidenc

276 Overall survival (OS), event-free survival, transplant-related mortality (TRM),

277 ters differ significantly in terms of 4-year event-free survival, with the lowest methylation cluster

278 The main outcome of interest was event-free survival.

279 s, CABG affords better major adverse cardiac event-free survival.

280 ed with increased toxicity without improving event-free survival.

281 vHD; overall survival; and chronic-GvHD-free event-free survival.

282 .005 and .02) were associated with a shorter event-free survival.

283 The primary endpoint for this study was event-free survival.

284 c graft-versus-host disease had no effect on event-free survival.

285 te, more frequent reinduction, and decreased event-free survival.

286 Our primary endpoint was event-free survival.

287 oved pathological complete response rate and event-free survival.

288 agnosis of which were highly associated with event-free survival.

289 iations with disease progression and reduced event-free survival.

290 (P=0.036) were independently associated with event-free survival.

291 f the bundled-payment program on overall and event-free survival.

292 The primary end point was 2-year event-free survival; the planned accrual was 38 patients

293 Major cardiovascular adverse events-free survival was worse in patients with MVO (P=0

294 Kaplan-Meier (event-free) survival estimates were used for the endpoin

295 2 positive had significantly worse five-year event-free-survival (33% vs 64%, p = 0.03 and 14% vs 59%

296 correlated with immune cell infiltration and event-free-survival (EFS).

297 ian follow-up of 5.4 years (IQR 3.1-6.8) the event-free-survival benefit from the addition of trastuz

298 nfiltrating lymphocytes (TILs) and five-year-event-free-survival were examined.

299 cal outcomes included overall survival (OS), event-free-survival, nonrelapse mortality (NRM), and gra

300 , duration of response, progression-free and event-free survivals, and safety.